Contraception
RSSArticles
-
Hormonal Contraception: A Risk Factor for Depression?
A population-based study suggests that hormonal contraception increases the risk of treatment for depression, but bias provides a more likely explanation for the association.
-
PCOS and Hormonal Contraception: A Tale of Two Syndromes?
Emerging evidence supports that two metabolic phenotypes exist among women with PCOS. For metabolically healthy PCOS patients, managing menstrual symptoms, anovulation and androgen excess with COCs provides a simple and well-tolerated treatment regimen. In contrast, PCOS patients with metabolic syndrome are at high risk for type 2 diabetes, and COC use may contribute to hyperinsulinemia, adverse lipid changes, and endothelial changes associated with adverse cardiovascular risk. The use of a levonorgestrel intrauterine device combined with spironolactone (to manage hyperandrogenism) and metformin (to manage hyperinsulinism) may offer advantages to metabolically unhealthy PCOS patients.
-
Is an Even Safer Combined Oral Contraceptive Pill Available?
ABSTRACT & COMMENTARY: New study has many advantages, including ascertainment of important confounding variables.
-
Still Highly Effective: LNG IUS 52 mg at 7 Years
Data from a large randomized study conducted by the World Health Organization demonstrate that pregnancy rates do not increase after year five, and support the continued use of the levonorgestrel intrauterine system 52 mg for contraception through seven years.
-
Immediate Postpartum IUD Insertion: Ready for Prime Time?
It is no secret that long-acting reversible contraception, such as intrauterine devices and implants, are among the most effective methods.
-
When Do Combined Oral Contraceptives Start Working After Ulipristal Acetate Emergency Contraception?
In this randomized, controlled trial of the effects of combined oral contraceptives on ovarian activity after taking ulipristal acetate, investigators found that some women needed up to 14 days to achieve ovarian quiescence. Therefore, abstinence or backup contraception should be used during that time.
-
Liletta: A New LNG-IUS Option
Initial clinical results with a new 52 mg levonorgestrel intrauterine system recently introduced to the market and approved for three years of use are similar to those seen with the existing system.
-
Why Aren’t Women Using Contraception?
ABSTRACT & COMMENTARY: This cross-sectional study highlights new risk factors for nonuse of contraception among women at risk for unintended pregnancy.
-
Isotretinoin and Contraception: Should iPLEDGE Be Changed?
In this study of female dermatologic patients, knowledge of the typical effectiveness of contraceptive methods increased after viewing a simple information sheet. Given the teratogenicity of isotretinoin, expanding the use of highly effective contraceptive methods among women of child-bearing potential using this medication is essential.
-
Low-lying Intrauterine Devices: To Remove or Not to Remove?
It is not uncommon that we receive reports from radiology regarding the location of an intrauterine device (IUD) in a patient that we have sent for a pelvic ultrasound examination for an entirely different reason (e.g., an adnexal mass). These incidental findings of low-lying or malpositioned IUDs are a conundrum for the practitioner.